Pentoxifylline and tocopherol in the management of patients with osteoradionecrosis, the Portsmouth experience.
Osteoradionecrosis of the jaw remains the most problematic consequence of radiotherapy for the management of head and neck cancer. Treatment is often complex and multimodal. New theories on its pathophysiology have allowed the development of potential treatment modalities, including the use of pentoxifylline and tocopherol. In this retrospective case series we examined the outcomes of patients with ORN prescribed pentoxifylline and tocopherol.
Department of Oral & Maxillofacial Surgery, Queen Alexandra Hospital, Portsmouth PO6 3LY, United Kingdom. niall mcleod@yahoo.co.uk
N M H
NM
McLeod
C A
CA
Pratt
T K
TK
Mellor
P A
PA
Brennan
D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007571:Jaw Diseases / Q000145:classification / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000532:radiotherapy; D020360:Neoadjuvant Therapy; D009959:Oropharyngeal Neoplasms / Q000532:radiotherapy; D010025:Osteoradionecrosis / Q000145:classification / Q000188:drug therapy*; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D024505:Tocopherols / Q000008:administration & dosage / Q000627:therapeutic use*; D014062:Tongue Neoplasms / Q000532:radiotherapy; D016896:Treatment Outcome
D000975:Antioxidants; D011837:Radiation-Protective Agents; D024505:Tocopherols; D010431:Pentoxifylline